<DOC>
	<DOCNO>NCT02361866</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness ( immunogeneicity ) safety 'GC1107 ' administer intramuscularly healthy Adults .</brief_summary>
	<brief_title>To Evaluate Effectiveness ( Immunogeneicity ) Safety 'GC1107 ' Administered Intramuscularly Healthy Adults</brief_title>
	<detailed_description>Randomized , double blind , multicenter , phaseⅢ study</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy Korean adult ( age : 18 year ) get basic vaccination DTP ( Diphtheria , tetanus , pertussis ) past Subjects willing provide write informed consent able comply requirement study subject already get additional vaccination Td within 5 year subject antitoxin diphtheria tetanus ≥1.0 IU/mL ( ELISA ) applicable step I subject recover acute disease within 2 week subject medical history allergic disease related component investigational drug get treatment blood product immunoglobulin product within 3 month female pregnant female breastfeed subject infect diphtheria tetanus subject experience severe adverse event diphtheria tetanus vaccination Subjects schedule participate clinical trial study study Subjects participate clinical trial within 4 week administration study Those take medicine affect study vaccinate vaccine Subject receive adrenocortical hormone immunosuppressive drug within 4weeks enrollment Subjects history chronic disease obstacle study . Subjects episode acute febrile ( least 37.4 ) injection vaccine study Subject plan operation study . Individuals clinically significant medical psychological condition consider investigator ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>